These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 7784616)

  • 21. Follow-up of ovarian and primary peritoneal carcinoma: the value of physical examination in patients with pretreatment elevated CA125 levels.
    Menczer J; Chetrit A; Sadetzki S; Golan A; Levy T
    Gynecol Oncol; 2006 Oct; 103(1):137-40. PubMed ID: 16564077
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship of preoperative serum CA-125 to survival in epithelial ovarian carcinoma.
    Geisler JP; Miller GA; Lee TH; Harwood RM; Wiemann MC; Geisler HE
    J Reprod Med; 1996 Mar; 41(3):140-2. PubMed ID: 8778409
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic significance of CA 125 and TPS levels after 3 chemotherapy courses in ovarian cancer patients.
    van Dalen A; Favier J; Burges A; Hasholzner U; de Bruijn HW; Dobler-Girdziunaite D; Dombi VH; Fink D; Giai M; McGing P; Harlozinska A; Kainz C; Markowska J; Molina R; Sturgeon C; Bowman A; Einarsson R
    Gynecol Oncol; 2000 Dec; 79(3):444-50. PubMed ID: 11104617
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Serum CA-15.3 and CEA patterns in postsurgical follow-up, and in monitoring clinical course of metastatic cancer in patients with breast carcinoma.
    al-Jarallah MA; Behbehani AE; el-Nass SA; Temim L; Ebraheem AK; Ali MA; Szymendera JJ
    Eur J Surg Oncol; 1993 Feb; 19(1):74-9. PubMed ID: 8436243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Diagnosis of the recurrence of epithelial ovarian cancer with the tumor marker CA 125].
    Sevelda P; Wagner G
    Wien Klin Wochenschr; 1987 Nov; 99(21):768-70. PubMed ID: 3480655
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pretreatment CA-125 and risk of relapse in advanced ovarian cancer.
    Markman M; Liu PY; Rothenberg ML; Monk BJ; Brady M; Alberts DS
    J Clin Oncol; 2006 Mar; 24(9):1454-8. PubMed ID: 16549840
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum CA-125 in relation to adnexal dysplasia and cancer in women at hereditary high risk of ovarian cancer.
    Hermsen BB; von Mensdorff-Pouilly S; Berkhof J; van Diest PJ; Gille JJ; Menko FH; Blankenstein MA; Kenemans P; Verheijen RH
    J Clin Oncol; 2007 Apr; 25(11):1383-9. PubMed ID: 17416858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.
    Mahner S; Woelber L; Jung S; Eulenburg CZ; Ihnen M; Schwarz J; Sehouli J; Jaenicke F
    Anticancer Res; 2009 Jul; 29(7):2817-21. PubMed ID: 19596967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The value of serum and tissular expression of CA 125 antigen, in evaluation of the response to second line chemotherapy for the relapsed ovarian carcinoma.
    Bădulescu F; Bădulescu A; Schenker M; Popescu CF; Stoica Z
    Rom J Morphol Embryol; 2005; 46(4):329-34. PubMed ID: 16688372
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relapse and survival in early-stage ovarian cancer.
    Lenhard SM; Bufe A; Kümper C; Stieber P; Mayr D; Hertlein L; Kirschenhofer A; Friese K; Burges A
    Arch Gynecol Obstet; 2009 Jul; 280(1):71-7. PubMed ID: 19093129
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Clinical value of the estimation of growth kinetics of primary ovarian cancer recurrences by CA125 doubling time].
    Riedinger JM; Coudert B; Barillot I; Buffenoir G; Mayer F; Fargeot P; Cuisenier J; Guerrin J
    Bull Cancer; 1997 Sep; 84(9):855-60. PubMed ID: 9435806
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Borderline ovarian tumors: a series of 43 patients].
    Darai E; Teboul J; Walker-Combrouze F; Fauconnier A; Bénifla JL; Meneux E; Panel P; Benzakine Y; Tardif D; Madelenat P
    Contracept Fertil Sex; 1997 Dec; 25(12):933-8. PubMed ID: 9497606
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serum CA 125 level allows early identification of nonresponders during induction chemotherapy.
    Makar AP; Kristensen GB; Børmer OP; Tropé CG
    Gynecol Oncol; 1993 Apr; 49(1):73-9. PubMed ID: 8482563
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Follow-up of treated cancers of the ovary].
    Pecking A; Pichon MF
    Rev Prat; 1997 Jun; 47(11):1211-5. PubMed ID: 9238817
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [The role of tumor marker CA 125 in the treatment of ovarian cancer].
    Porsbjerg CM; Sørensen JB; Lund BA
    Ugeskr Laeger; 1998 Feb; 160(7):995-1000. PubMed ID: 9477746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum half-life of CA 125 during early chemotherapy as an independent prognostic variable for patients with advanced epithelial ovarian cancer: results of a multicentric Italian study.
    Gadducci A; Zola P; Landoni F; Maggino T; Sartori E; Bergamino T; Cristofani R
    Gynecol Oncol; 1995 Jul; 58(1):42-7. PubMed ID: 7789889
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural, or pericardial fluids.
    Sevinc A; Buyukberber S; Sari R; Kiroglu Y; Turk HM; Ates M
    Gynecol Oncol; 2000 May; 77(2):254-7. PubMed ID: 10785474
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Significance of preoperative serum CA-125 levels in the prediction of lymph node metastasis in epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Acta Obstet Gynecol Scand; 2008; 87(11):1136-42. PubMed ID: 18951217
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
    Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
    Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
    [TBL] [Abstract][Full Text] [Related]  

  • 40. COX-2 and preoperative CA-125 level are strongly correlated with survival and clinical responsiveness to chemotherapy in ovarian cancer.
    Raspollini MR; Amunni G; Villanucci A; Boddi V; Taddei GL
    Acta Obstet Gynecol Scand; 2006; 85(4):493-8. PubMed ID: 16612714
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.